Jim Cramer says he's standing by Eli Lilly after rival's GLP-1 lawsuit. Here's why

The near-term winners are the names with visible monetization pathways, not the ones with merely better narrative. Intel’s foundry win is important mainly as a signaling event: it can improve customer acquisition odds and keep the multiple from compressing further, but unless this turns into a string of repeat design wins, the financial impact is still too small to offset the fixed-cost burden of a foundry buildout. The more important second-order trade is in semis: a better Intel perception can support SOXX/SMH breadth, but it also highlights how much of the group’s multiple is being driven by AI-capex hope rather than end-demand evidence.

In enterprise software, the market is punishing CRM for the same reason it is rewarding MSFT: investors want proof that AI monetization is showing up in billable usage, not just product launches. CRM looks vulnerable to another leg lower if Agentforce uptake remains anecdotal into the next earnings cycle, while MSFT has a more durable backstop from Azure capacity and bundled pricing power; the key risk is that OpenAI governance noise or Xbox margin pressure distracts from that core cloud thesis. Relative-value wise, the cleaner expression is long MSFT / short CRM, not an outright tech beta bet.

In obesity, the litigation read-through is mostly noise unless it changes prescribing behavior or regulatory language. The real driver remains share capture between LLY and NVO in a market where formulation, dose escalation, and international rollout matter more than ad-copy disputes; that favors LLY as the operationally stronger compounder, while NVO’s risk is that it loses time in the oral race and cedes mindshare. The contrarian view is that the selloff in NVO may be overdone if higher-dose Wegovy uptake accelerates faster than expected, which would make the current legal overhang a buying opportunity rather than a thesis break.